Abstract: The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.
Type:
Application
Filed:
December 16, 2022
Publication date:
February 6, 2025
Applicant:
Instil Bio, Inc.
Inventors:
Gray Kueberuwa, Sifat Ahmed, Kenny Choi, Holly Bethany Crookes, Robson Dossa, Jeremy Garibay, James Huston Glenn, IV, Paulina Nowosiad, Fitore Vlashi, Maize Wang
Abstract: The subject matter described herein is directed to methods for determining the potency of isolated and expanded tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, and compositions involving the same and methods of treatment involving the same.
Abstract: The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.
Type:
Application
Filed:
June 22, 2022
Publication date:
June 20, 2024
Applicant:
Instil Bio, Inc.
Inventors:
Sifat Ahmed, Kenny Choi, Holly Bethany Crookes, Robson Dossa, Jeremy Garibay, James Huston Glenn, IV, Paulina Nowosiad, Fitore Vlashi, Maize Wang
Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
Type:
Grant
Filed:
June 15, 2022
Date of Patent:
April 2, 2024
Assignees:
Instil Bio (UK) Limited, Instil Bio, Inc.
Inventors:
John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
© 2025 Justia
